---
title: "MitoCareX Bio Advances Mitochondrial Drug Research Under N2OFF Inc"
description: "N2OFF, Inc. (NASDAQ: NITO) has announced advancements by its subsidiary, MitoCareX Bio Ltd., in developing small-molecule drugs targeting human mitochondrial carriers. Utilizing the MITOLINE™ algorith"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274518071.md"
published_at: "2026-02-02T13:05:13.000Z"
---

# MitoCareX Bio Advances Mitochondrial Drug Research Under N2OFF Inc

> N2OFF, Inc. (NASDAQ: NITO) has announced advancements by its subsidiary, MitoCareX Bio Ltd., in developing small-molecule drugs targeting human mitochondrial carriers. Utilizing the MITOLINE™ algorithm, MitoCareX Bio aims to address conditions like cancer and metabolic diseases linked to mitochondrial dysfunction. This initiative supports the company's precision pipeline for treating rare inherited disorders. The information is generated by Public Technologies and should not be considered financial or legal advice.

N2OFF, Inc. (NASDAQ: NITO) has highlighted the work of its wholly-owned subsidiary, MitoCareX Bio Ltd., a specialty biotechnology company focused on developing small-molecule drugs that target human mitochondrial carriers. MitoCareX Bio utilizes proprietary approaches, including the MITOLINE™ algorithm, to model, screen, and validate compounds that target the SLC25A family of mitochondrial carriers. These efforts support the company’s precision pipeline addressing conditions such as cancer, metabolic diseases, and rare inherited disorders linked to mitochondrial dysfunction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646968-en) on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [NITO.US - N2OFF](https://longbridge.com/en/quote/NITO.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [NXTS.US - Nexentis Tech](https://longbridge.com/en/quote/NXTS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BUZZ-Tevogen rises on plans to buy majority stake in digital health firm Sciometrix | Shares of drug developer Tevogen Biorise 13.7% to 33 cents premarketCo signs letter of intent to buy a majority stake in | [Link](https://longbridge.com/en/news/277058905.md) |
| FDA approves Ascendis Pharma’s weekly Yuviwel for paediatric dwarfism | The FDA has granted accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide) for treating paediatric achondropl | [Link](https://longbridge.com/en/news/277455732.md) |
| Beam Therapeutics tops Q4 profit estimates, signs financing deal | Beam Therapeutics reported Q4 earnings that exceeded analyst expectations, with EPS at $2.33 and net income of $244.3 mi | [Link](https://longbridge.com/en/news/276730924.md) |
| Delcath Q4 revenue rises 37%, beats estimates | Delcath Systems reported a 37% increase in Q4 revenue, surpassing analyst expectations with $20.73 million. Despite a ne | [Link](https://longbridge.com/en/news/277046688.md) |
| Craig-Hallum Sticks to Their Buy Rating for Apogee Therapeutics (APGE) | Craig-Hallum analyst Adam Vogel has maintained a Buy rating on Apogee Therapeutics (APGE) with a price target of $116.00 | [Link](https://longbridge.com/en/news/277492684.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.